Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Authors
Keywords
-
Journal
Nanoscale
Volume 14, Issue 4, Pages 1054-1074
Publisher
Royal Society of Chemistry (RSC)
Online
2022-01-01
DOI
10.1039/d1nr03831a
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates
- (2021) Yin-Feng Kang et al. ACS Nano
- Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles
- (2021) Uri Elia et al. ACS Nano
- A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
- (2021) Tiong Kit Tan et al. Nature Communications
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021
- (2021) et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice
- (2021) Abigail E. Powell et al. ACS Central Science
- Self-assembled mRNA vaccines
- (2021) Jeonghwan Kim et al. ADVANCED DRUG DELIVERY REVIEWS
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera
- (2021) Daming Zhou et al. CELL
- Novel lipid combination for delivery of plasmid DNA to immune cells in the spleen
- (2021) Seigo Kimura et al. JOURNAL OF CONTROLLED RELEASE
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- (2021) Dami A. Collier et al. NATURE
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
- (2021) Zijun Wang et al. NATURE
- BNT162b vaccines protect rhesus macaques from SARS-CoV-2
- (2021) Annette B. Vogel et al. NATURE
- A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
- (2021) Qingrui Huang et al. Nature Communications
- Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine
- (2021) Lara Milane et al. Drug Delivery and Translational Research
- Immunogenicity Risk Profile of Nanobodies
- (2021) Chloé Ackaert et al. Frontiers in Immunology
- Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2021
- (2021) A. Patricia Wodi et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- An Update on Self-Amplifying mRNA Vaccine Development
- (2021) Anna K. Blakney et al. Vaccines
- Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys
- (2021) Heng Li et al. BIOCONJUGATE CHEMISTRY
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
- (2021) Yair Herishanu et al. BLOOD
- SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
- (2021) Alona Kuzmina et al. Cell Host & Microbe
- Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients
- (2021) Liane Rabinowich et al. JOURNAL OF HEPATOLOGY
- A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice
- (2021) Ruklanthi de Alwis et al. MOLECULAR THERAPY
- Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
- (2021) Prabhu S. Arunachalam et al. NATURE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage
- (2021) Frank Gambino et al. Cell Reports
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
- (2021) Megan Wallace et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
- (2021) Linling He et al. Science Advances
- Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
- (2021) Kirill V. Kalnin et al. npj Vaccines
- BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19
- (2021) Rui-Ru Ji et al. Vaccines
- Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept
- (2021) Nathalie Chavarot et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Cellular and humoral immune response after mRNA‐1273 SARS‐CoV‐2 vaccine in liver and heart transplant recipients
- (2021) Sabina Herrera et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Cellular and humoral response after MRNA‐1273 SARS‐CoV‐2 vaccine in kidney transplant recipients
- (2021) David Cucchiari et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Neutralizing antibodies for the prevention and treatment of COVID-19
- (2021) Lanying Du et al. Cellular & Molecular Immunology
- COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge
- (2021) Anthony T. DiPiazza et al. IMMUNITY
- Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial
- (2021) Vivek Shinde et al. LANCET INFECTIOUS DISEASES
- Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection
- (2021) Uri Elia et al. NANO LETTERS
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
- (2021) Paul T. Heath et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- (2021) Stephen J. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
- (2021) Neeltje van Doremalen et al. Viruses-Basel
- A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
- (2021) Jiandong Huo et al. Nature Communications
- Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection
- (2021) Qibin Geng et al. PLoS Pathogens
- The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates
- (2021) Gang Ye et al. eLife
- Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
- (2021) Kathleen Dooling et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
- (2021) Wesley H. Self et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children
- (2021) Audrey Dionne et al. JAMA Cardiology
- SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques
- (2021) Carolina Garrido et al. Science Immunology
- Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
- (2021) Luca Coppeta et al. Vaccines
- Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response
- (2021) Yoav Rechavi et al. Vaccines
- Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2; a prospective study
- (2021) Maria Gavriatopoulou et al. Blood Advances
- Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia
- (2021) Abanoub Riad et al. Pharmaceuticals
- Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers
- (2021) Miloslav Klugar et al. Biology-Basel
- Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database
- (2021) Rimple Kaur et al. International Journal of General Medicine
- Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: a case report
- (2021) Ryuhei Takeyama et al. ACTA NEUROCHIRURGICA
- Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
- (2021) Jan Melin et al. BMC IMMUNOLOGY
- Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
- (2021) Yamato Nishiguchi et al. BMC Neurology
- Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey
- (2021) Shirley Shapiro Ben David et al. CLINICAL IMMUNOLOGY
- Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment
- (2021) Tania Buttiron Webber et al. EUROPEAN JOURNAL OF CANCER
- Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups
- (2021) Clodoveo Ferri et al. JOURNAL OF AUTOIMMUNITY
- Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
- (2021) Vivek Naranbhai et al. JOURNAL OF CLINICAL ONCOLOGY
- Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
- (2021) Yaki Saciuk et al. JOURNAL OF INFECTIOUS DISEASES
- B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients
- (2021) Eva Schrezenmeier et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
- (2021) Noam Barda et al. LANCET
- Immunogenicity and Adverse Effects of the 2‐Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients
- (2021) Yana Davidov et al. LIVER TRANSPLANTATION
- Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
- (2021) Rachna T. Shroff et al. NATURE MEDICINE
- Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study
- (2021) Jorge Antonio Esquivel-Valerio et al. RHEUMATOLOGY INTERNATIONAL
- Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants
- (2021) Linda van Oosten et al. mBio
- Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
- (2021) Dafna Yahav et al. BMJ Open
- Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
- (2021) Neil Formica et al. PLOS MEDICINE
- Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model
- (2021) Kei Haga et al. PLoS Pathogens
- Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days
- (2021) Sergio Gil-Manso et al. Frontiers in Immunology
- Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic — United States, July 2020–July 2021
- (2021) Geoffrey French et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
- (2021) Anne M. Hause et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
- (2021) Kate R. Woodworth et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
- (2021) Yi-Nan Zhang et al. Science Advances
- Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients
- (2021) Filippo Massa et al. EBioMedicine
- A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
- (2021) Kathryn McGuckin Wuertz et al. npj Vaccines
- COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
- (2021) Farren Basil Shaw Briggs et al. Neurology-Neuroimmunology & Neuroinflammation
- BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease
- (2021) Claudia Rossi et al. Vaccines
- Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia
- (2021) Julien Marlet et al. Vaccines
- Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
- (2021) José G. Montoya et al. Microbiology Spectrum
- Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study
- (2021) Abanoub Riad et al. Pharmaceuticals
- Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco
- (2021) Marouane Melloul et al. Microbiology Resource Announcements
- Vitamin E Scaffolds of pH-Responsive Lipid Nanoparticles as DNA Vaccines in Cancer and Protozoan Infection
- (2020) Mio Maeta et al. MOLECULAR PHARMACEUTICS
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
- (2020) Ning Wang et al. Frontiers in Microbiology
- An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies
- (2020) Shibo Jiang et al. Emerging Microbes & Infections
- Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
- (2020) Abishek Wadhwa et al. Pharmaceutics
- The promise of mRNA vaccines: a biotech and industrial perspective
- (2020) Nicholas A. C. Jackson et al. npj Vaccines
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
- (2020) Wanbo Tai et al. Cellular & Molecular Immunology
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- Cell entry mechanisms of SARS-CoV-2
- (2020) Jian Shang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
- (2020) Shibo Jiang et al. TRENDS IN IMMUNOLOGY
- Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
- (2020) Wanbo Tai et al. ANTIVIRAL RESEARCH
- A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
- (2020) Wanbo Tai et al. CELL RESEARCH
- Generation and design of nanobodies
- (2020) Serge Muyldermans FEBS Journal
- A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
- (2020) Dorottya Laczkó et al. IMMUNITY
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
- (2020) Kizzmekia S. Corbett et al. NATURE
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
- (2020) Jiangdong Huo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
- (2020) Kizzmekia S. Corbett et al. NEW ENGLAND JOURNAL OF MEDICINE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nanoparticles presenting clusters of CD4 expose a universal vulnerability of HIV-1 by mimicking target cells
- (2020) Magnus A. G. Hoffmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates
- (2020) Jesse H. Erasmus et al. Science Translational Medicine
- Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
- (2020) Paul F. McKay et al. Nature Communications
- Nanotechnology-based antiviral therapeutics
- (2020) Malobika Chakravarty et al. Drug Delivery and Translational Research
- Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2
- (2020) Shibo Jiang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies
- (2020) Naru Zhang et al. Expert Review of Vaccines
- Self-amplifying RNA vaccines for infectious diseases
- (2020) Kristie Bloom et al. GENE THERAPY
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
- (2020) Ugur Sahin et al. NATURE
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
- (2020) Leo Hanke et al. Nature Communications
- Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
- (2020) Xiaojing Chi et al. Nature Communications
- A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone
- (2020) Baoshan Zhang et al. Scientific Reports
- A new generation of vaccines based on alphavirus self-amplifying RNA
- (2020) María Cristina Ballesteros-Briones et al. Current Opinion in Virology
- Solid Lipid Nanoparticle Carrier Platform Containing Synthetic TLR4 Agonist Mediates Non-Viral DNA Vaccine Delivery
- (2020) Jasmine E. Francis et al. Vaccines
- Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines
- (2020) Naru Zhang et al. Vaccines
- SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation
- (2020) Katlyn Lederer et al. IMMUNITY
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
- (2020) Alicia T. Widge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
- (2020) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
- (2020) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Neutralizing antibodies for the treatment of COVID-19
- (2020) Shibo Jiang et al. Nature Biomedical Engineering
- Novel Applications of Nanotechnology in Controlling HIV and HSV Infections
- (2020) Sai Akilesh M et al. Current Drug Research Reviews
- Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
- (2019) Lei He et al. Viruses-Basel
- A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F Nanobody®, in moderate-to-severe psoriasis
- (2019) Danka Svecova et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Nanobody approval gives domain antibodies a boost
- (2019) Chris Morrison NATURE REVIEWS DRUG DISCOVERY
- Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures
- (2019) Lindsay Broadbent et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structure and development of single domain antibodies as modules for therapeutics and diagnostics
- (2019) Robert J Hoey et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
- (2019) Sergio Linares-Fernández et al. TRENDS IN MOLECULAR MEDICINE
- Prospects for a MERS-CoV spike vaccine
- (2018) Yusen Zhou et al. Expert Review of Vaccines
- Caplacizumab: First Global Approval
- (2018) Sean Duggan DRUGS
- Origin and evolution of pathogenic coronaviruses
- (2018) Jie Cui et al. NATURE REVIEWS MICROBIOLOGY
- Nanoparticle Vaccines Against Infectious Diseases
- (2018) Rashmirekha Pati et al. Frontiers in Immunology
- Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins
- (2017) Young-Tae Lee et al. Journal of Biomedical Nanotechnology
- MERS-CoV spike protein: a key target for antivirals
- (2016) Lanying Du et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Vaccines for the prevention against the threat of MERS-CoV
- (2016) Lanying Du et al. Expert Review of Vaccines
- Structure, Function, and Evolution of Coronavirus Spike Proteins
- (2016) Fang Li Annual Review of Virology
- DNA Mediated Vaccines Delivery Through Nanoparticles
- (2015) Muhammad Ali A. Shah et al. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
- Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans
- (2015) Marie Borggren et al. Human Vaccines & Immunotherapeutics
- Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies
- (2014) Fang Li JOURNAL OF VIROLOGY
- Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development
- (2013) L. Du et al. JOURNAL OF VIROLOGY
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
- (2012) Ali M. Zaki et al. NEW ENGLAND JOURNAL OF MEDICINE
- The growing role of nanotechnology in combating infectious disease
- (2011) Karin Blecher et al. Virulence
- The spike protein of SARS-CoV — a target for vaccine and therapeutic development
- (2009) Lanying Du et al. NATURE REVIEWS MICROBIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started